Last reviewed · How we verify
Placebo for SCH 39641
This is a placebo control with no active pharmacological mechanism.
At a glance
| Generic name | Placebo for SCH 39641 |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials. It is used to establish the baseline efficacy and safety profile of the active investigational drug SCH 39641 through blinded comparison.
Approved indications
Common side effects
Key clinical trials
- A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751) (PHASE3)
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) (PHASE2, PHASE3)
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for SCH 39641 CI brief — competitive landscape report
- Placebo for SCH 39641 updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI